152 related articles for article (PubMed ID: 28541392)
1. Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al.
Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
Ann Oncol; 2017 Sep; 28(9):2316. PubMed ID: 28541392
[No Abstract] [Full Text] [Related]
2. Reply to 'letter to the editor of Annals of Surgical Oncology concerning "robotic versus open pancreatectomy: a systematic review and meta-analysis",' by Petrucciani Niccolò, et al. (ASO-2013-09-1427).
Zhang J; Wu WM; You L; Zhao YP
Ann Surg Oncol; 2014 Sep; 21(9):3161-2. PubMed ID: 24743906
[No Abstract] [Full Text] [Related]
3. Reply to Letter: "Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer".
Takahashi H; Ishikawa O
Ann Surg; 2015 Dec; 262(6):e103-4. PubMed ID: 24670859
[No Abstract] [Full Text] [Related]
4. Borderline resectable pancreatic cancer: an evolving concept.
Petrucciani N; Debs T; Nigri G; D'Angelo F; Gugenheim J; Ramacciato G
Ann Oncol; 2017 Sep; 28(9):2315. PubMed ID: 28911082
[No Abstract] [Full Text] [Related]
5. Borderline resectable pancreatic cancer: More than an anatomical concept.
Petrelli F; Inno A; Barni S; Ghidini A; Labianca R; Falconi M; Reni M; Cascinu S;
Dig Liver Dis; 2017 Feb; 49(2):223-226. PubMed ID: 27931968
[TBL] [Abstract][Full Text] [Related]
6. Letter to the Editor: Comment on: Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.
Jonas E; Krige J; Bernon M
J Gastrointest Cancer; 2021 Sep; 52(3):1188-1189. PubMed ID: 34173179
[No Abstract] [Full Text] [Related]
7. Reply to Letter to the Editor "Re: Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery".
Kondo N
Dig Surg; 2022; 39(5-6):274-275. PubMed ID: 36315986
[No Abstract] [Full Text] [Related]
8. Reply to the letter to the editor regarding "The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer: Methodological issues".
Ito T; Imai T; Omae K; Sugiura T; Uesaka K
Pancreatology; 2017; 17(5):650. PubMed ID: 28693975
[No Abstract] [Full Text] [Related]
9. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Callery et al.
Choti MA; Dixon E; Tyler D
Ann Surg Oncol; 2009 Jul; 16(7):1734-5. PubMed ID: 19390901
[No Abstract] [Full Text] [Related]
10. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
11. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
Wang G; Zhou D
Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
[TBL] [Abstract][Full Text] [Related]
12. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
[TBL] [Abstract][Full Text] [Related]
13. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society.
Yamada S; Fujii T; Takami H; Hayashi M; Iwata N; Kanda M; Tanaka C; Sugimoto H; Nakayama G; Koike M; Fujiwara M; Kodera Y
Surgery; 2017 Oct; 162(4):784-791. PubMed ID: 28655416
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al.
Adams RB; Allen PJ
Ann Surg Oncol; 2009 Jul; 16(7):1745-50. PubMed ID: 19396494
[No Abstract] [Full Text] [Related]
15. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation.
Hoffe S; Rao N; Shridhar R
Semin Radiat Oncol; 2014 Apr; 24(2):113-25. PubMed ID: 24635868
[TBL] [Abstract][Full Text] [Related]
16. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
17. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.
Ambe CM; Nguyen P; Centeno BA; Choi J; Strosberg J; Kvols L; Hodul P; Hoffe S; Malafa MP
Cancer Control; 2017; 24(5):1073274817729076. PubMed ID: 28975822
[TBL] [Abstract][Full Text] [Related]
18. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
19. Reply to Alizadeh's Letter to the Editor Re: Lu, P.Y. et al., Nutrients 2017, 9, 38.
Lu PY; Shu L; Shen SS; Chen XJ; Zhang XY
Nutrients; 2017 Jul; 9(7):. PubMed ID: 28686193
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
